Global Autoimmune Disease Treatment Market Size, Forecast, and Trend Highlights Over 2025-2037
Autoimmune Disease Treatment Market size was valued at USD 153.5 billion in 2024 and is projected to reach USD 343.1 billion by the end of 2037, rising at a CAGR of 7.8% during the forecast period, i.e., 2025-2037. In 2025, the industry size of autoimmune disease treatment is evaluated at USD 165 billion.
According to the WHO, the occurrence rate of autoimmune diseases, such as rheumatoid arthritis, psoriasis, and type I diabetes, around the world ranges between 5.1% and 10.3%. It also mentioned that the population of such patients in Europe crossed 12.8 million, where Germany and France accounted for 5.3 million and 3.9 million, respectively. This expanding demography is further creating a surge in innovative therapies, including biologics and immunosuppressants, fostering a substantial demand in the autoimmune disease treatment market. Moreover, advancements in diagnostic accuracy and widespread awareness about early prevention are accumulatively propelling cash inflow in this sector.
The ongoing inflation in raw material costs, R&D expenses, and regulatory compliance is escalating the key economic indicators in the autoimmune disease treatment market. In this regard, between 2023 and 2024, the U.S. Bureau of Labor Statistics (BLS) observed a 4.3% year-over-year (YoY) rise in the producer price index (PPI) for associated medications. Simultaneously, this upward trajectory followed through the consumer price index (CPI) for retailed products from this sector, with a 5.9% increase. Thus, despite the growing demand, a financial barrier is present across the globe due to the heightening payers' pricing volatilities for API, labor, and logistics. Furthermore, the collective efforts from both government and drug developers are being concentrated on maintaining comprehensive pricing.
Autoimmune Disease Treatment Market: Growth Drivers and Challenges
Growth Drivers
-
Shifting preference toward value-based healthcare: Considering the importance of affordability and accessibility in advanced solutions, several organizations are prioritizing the worldwide expansion of the autoimmune disease treatment market. In support of this cohort, clinical studies are establishing the cost-effectiveness and therapeutic efficiency of early intervention with products available in this sector. For instance, in 2022, the Agency for Healthcare Research and Quality (AHRQ) published a study on the advantages of using biologics to treat rheumatoid arthritis at an earlier stage. It concluded a 32.2% reduction in the need for hospital admissions and hence saved more than USD 4.2 billion for the healthcare system in the U.S. over 2 years.
- Proactive research activities and investments: Besides spreading awareness, the priority shift also dragged the focus on innovations in the autoimmune disease treatment market. Dedicated investors, spread across the global health industry, are backing this R&D goal by allocating significant capital. As per a report from the National Institute of Health (NIH), in 2024, the net investment in research, development, and deployment in this category totaled USD 18.8 billion. It further mentioned that over 65.2% of this amount was dedicated to biological development. In addition, acceleration in regulatory approvals also outstretched the territory of the pipeline in this field.
Historical Patient Growth and Its Impact on Market Expansion
The continuous enlargement of patient volume from 2010 to 2020 across the world reflected the formation of a strong base of consumer in the autoimmune disease treatment market. The gradual increase in the prevalence of related ailments in both developing and mature economies, including the U.S., Europe, Japan, India, and China, fueled this expansion in demography during the selected tenure. Additionally, the merchandise witnessed the effects of rapid aging and other comorbidities, pushing more companies and medical authorities to participate. Furthermore, the widespread inspired the biopharmaceutical industry to induce tailored pipelines of targeted therapies, shaping a reliable roadmap for supplying today's patient pool.
Historical Patient Growth (2010-2020)-Autoimmune Disease Treatment Users
|
Country |
2010 Patients (Million) |
2020 Patients (Million) |
Growth (%) |
Key Driver |
|
U.S. |
12.5 |
18.8 |
50.9% |
Biologic adoption (Humira, Enbrel) |
|
Germany |
4.3 |
6.6 |
54.9% |
Universal healthcare coverage |
|
France |
3.2 |
5.0 |
58.2% |
Early-diagnosis initiatives |
|
Spain |
2.4 |
3.7 |
56.6% |
Rheumatology specialty centers |
|
Australia |
1.0 |
1.6 |
66.8% |
PBS subsidized biologics |
|
Japan |
5.9 |
8.3 |
41.5% |
Aging population (RA focus) |
|
India |
14.6 |
24.4 |
67.7% |
Urbanization & diagnostics |
|
China |
21.8 |
43.0 |
97.8% |
Healthcare infrastructure expansion |
Feasible Expansion Models Shaping the Autoimmune Treatment Market
The transformative phase of the autoimmune disease treatment market is underlaid by the implementation of strategic operations and their commercial benefits. Thus, the success and milestones achieved by key players in this sector have drafted a guideline for new entrants and investors to generate maximum revenue. Their plan of action contained improvements in public access, standardization of biosimilars, localized production, and extensive R&D engagement. These approaches not only helped them mitigate the expected roadblocks but also fostered new business opportunities, expanding the sector's reach worldwide. Furthermore, their efforts to maintain alignment with sustainability criteria are shaping the current dynamics of this merchandise.
Revenue Feasibility Models (2020-2024)
|
Strategy |
Region |
Revenue Impact |
|
Local API Production |
China |
18.4% cost reduction |
|
Biosimilar Tendering |
Germany |
$2.2 billion savings (2023) |
|
Telemedicine Partnerships |
India |
12.4% revenue growth |
|
Value-Based Pricing |
UK |
90.1% coverage rate |
Challenge
-
Infrastructural insufficiencies in emerging markets: Despite the wide acceptance of the latest innovations in developed regions, underdeveloped countries still present inefficiency in supporting such advancements. This is becoming a major hurdle in reaching optimum progress in the autoimmune disease treatment market. Testifying this, the Ministry of Health in Brazil revealed that only 3 in every 10 major autoimmune medicines are covered under their national public health system. However, both companies and governments are bridging these gaps with massive investments and innovations in both diagnosis and treatment. For instance, the Brazilian government allocated a USD 300.2 million fund to improve the country's testing capacity.
Autoimmune Disease Treatment Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.8% |
|
Base Year Market Size (2024) |
USD 153.5 billion |
|
Forecast Year Market Size (2037) |
USD 343.1 billion |
|
Regional Scope |
|
Autoimmune Disease Treatment Segmentation
Drug Class (Biologics, Non-Steroidal Anti-Inflammatory Drugs, Corticosteroids, Disease-Modifying Anti-Rheumatic Drugs)
Based on drug class, the biologics segment is expected to hold the largest share of 48.1% in the autoimmune disease treatment market by the end of 2037. The presence of sufficient clinical evidence, demonstrating the exceptional capabilities and future possibilities of these therapeutics, is fueling this proprietorship. Particularly, the success of treating chronic ailments, such as rheumatoid arthritis and psoriasis, with TNF-alpha inhibitors fastened and simplified the way of attaining regulatory approvals for drug developers. As evidence, the FDA enabled accelerated clearance for next-generation biologics, including innovative IL-17/23 inhibitors. Moreover, the ease of commercializing innovations is fueling steady growth in this segment of autoimmune care.
Disease Type (Rheumatoid Arthritis, Psoriasis, Multiple Sclerosis, Type 1 Diabetes)
In terms of disease type, the rheumatoid arthritis segment is poised to dominate the autoimmune disease treatment market by capturing a 32.4% revenue share over the assessed timeline. The rapid spread of this illness and its severity among aged populations have made it a leading concern and focus for healthcare authorities and associated pharma pioneers. Additionally, the escalated pace of aging among people worldwide is establishing a predominant consumer base in this sector. In this regard, recent data released by the Centers for Disease Control and Prevention (CDC) predicted the count of adults, aged over 55, in the U.S. alone to surpass 78.5 million by 2035. Moreover, the heightening rate of biological adoption in this discipline is amplifying the cash inflow in this segment.
Our in-depth analysis of the global autoimmune disease treatment market includes the following segments:
|
Drug Class |
|
|
Disease Type |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAutoimmune Disease Treatment Industry - Regional Synopsis
North America Market Analysis
North America is anticipated to garner the highest revenue from the autoimmune disease treatment market, accounting for a 38.4% share, throughout the discussed period. The significantly high rate of incidence of associated ailments is the primary driver behind the region's leadership. In this regard, the NIH identified more than 23.6 million citizens of America as having autoimmune disorders. In addition, the number of new diagnoses across North America surpassed 8.5 million. This continuous demographic expansion represents a sustainable demand for advanced biologics and other related therapeutics, fostering a favorable trading atmosphere for both domestic and foreign biopharma developers and producers.
The U.S. is augmenting leadership in the regional autoimmune treatment market due to increased biologic adoption and a strong reimbursement structure. The country represents a progressive atmosphere with ongoing biological innovations and developed healthcare system, which can be testified by the magnifying R&D investments. For instance, in 2023, the research funding from the Federal government reached USD 5.1 billion. Simultaneously, Medicare coverage expanded by 15.3% from 2020 to 2024. Besides, in 2023, the acceleration in the process of FDA compliance broadened the range of products in this field with 14 new autoimmune medicines. Moreover, the emergence of biosimilars is evolving the dynamics in this marketplace.
APAC Market Statistics
Asia Pacific is projected to register the highest CAGR in the global autoimmune disease treatment market from 2025 to 2037. The region's propagation is predominantly pledged to infrastructural modernization, a rapidly aging population, and a strong emphasis on generic production. As evidence, the proportion of older citizens, aged 65 and over, in Japan is showing a possibility of acquiring 30.1% by 2030. Thus, the net spending on biologics in this country surpassed USD 3.4 billion, as per the Ministry of Health, Labour and Welfare. Moreover, with the focus on enhancing affordability, emerging landscapes such as China and India are establishing an influential impact on the economic output in this sector.
In 2024, the National Medical Products Administration in China recorded approximately 1.6 million yearly incidences of autoimmune ailments nationwide. As a response, the governing body of this country increased its expenditure on this category by 15.2% from 2019 to 2024. This reflects a sustainable demand and substantial capital influx in the China autoimmune disease treatment market. Furthermore, the country is ensuring continuous expansion and progress in this merchandise with enhanced insurance coverage and funding volume. For instance, in 2024, the Nation Healthcare Security Administration incorporated 7 additional biologics in their national reimbursement policy, which cut per-patient costs by 50.4%.
Companies Dominating the Autoimmune Disease Treatment Market
Currently, a significant revenue share of 48.2% in the autoimmune treatment market is controlled by the collective output from AbbVie, J&J, Roche, Novartis, and Pfizer. Their strategic augmentation toward product innovation and commercialization helped consolidate this leadership. In addition, they are proactively investing and involved in the cohort of extensive exploration and penetration of their existing pipelines while maintaining alignment with the latest autoimmune disease treatment market trends. For instance, in 2025, Novartis advanced its CAR-T therapy portfolio to expand applications for treating lupus. Similarly, BMS allocated USD 14.3 billion in capital to leverage its leadership in immunology by acquiring Turning Point.
Top 20 of this cohort of innovators inclue:
|
Company Name |
Country |
Market Share |
Industry Focus |
|
AbbVie |
U.S. |
12.6% |
Leader in biologics (Humira, Skyrizi for psoriasis/RA) |
|
Johnson & Johnson |
U.S. |
10.3% |
Immunology blockbusters (Stelara, Tremfya) |
|
Roche |
Switzerland |
9.9% |
Biologics (Rituxan, Actemra) + companion diagnostics |
|
Novartis |
Switzerland |
8.7% |
CAR-T therapies (Kymriah for lupus) & Cosentyx (psoriasis/AS) |
|
Pfizer |
U.S. |
7.5% |
JAK inhibitors (Xeljanz for RA) & biosimilars |
|
Amgen |
U.S. |
xx% |
Enbrel (RA), biosimilars (Amjevita) |
|
Bristol-Myers Squibb |
U.S. |
xx% |
Orencia (RA), Sotyktu (psoriasis) |
|
Eli Lilly |
U.S. |
xx% |
Taltz (psoriasis/AS), Olumiant (RA) |
|
UCB |
Belgium |
xx% |
Cimzia (RA/psoriasis), neurology-autoimmune pipeline |
|
Sanofi |
France |
xx% |
Dupixent (eczema/asthma), autoimmune rare disease focus |
|
Merck KGaA |
Germany |
xx% |
Rebif (multiple sclerosis), Erbitux (RA) |
|
Takeda |
Japan |
xx% |
Entyvio (IBD), plasma-derived therapies |
|
AstraZeneca |
UK |
xx% |
Fasenra (eosinophilic diseases), rare autoimmune pipeline |
|
Gilead Sciences |
U.S. |
xx% |
Jyseleca (RA), Kite Pharma CAR-T expansion |
|
Biogen |
U.S. |
xx% |
MS drugs (Tysabri, Tecfidera) |
|
Celltrion |
South Korea |
xx% |
Biosimilars (Remsima, Truxima) dominating EU/Asia |
|
Daiichi Sankyo |
Japan |
xx% |
Collaborations with U.S./EU firms on RA/psoriasis |
|
Biocon |
India |
xx% |
Biosimilars (adalimumab, trastuzumab) for cost-sensitive markets |
|
CSL Limited |
Australia |
xx% |
Plasma therapies for autoimmune disorders (Privigen) |
|
Pharmaniaga |
Malaysia |
xx% |
Localized biosimilars & insulin for ASEAN markets |
In the News
- In June 2024, Argenx launched VYVGART Hytrulo, expanding its use beyond myasthenia gravis to treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a condition affecting ~40,010 U.S. patients. The drug taps into a USD 1.3 billion market opportunity, driving a 20.1% increase in Q2 2024 revenue.
- In May 2024, Amgen received FDA accelerated approval for tarlatamab (Imdelltra), a first-in-class BiTE therapy targeting DLL3 in small cell lung cancer (SCLC), which has few treatment options. The drug is projected to generate USD 500.1 million annually by 2025, reinforcing the company’s position in oncology and autoimmune-adjacent therapies.
Author Credits: Radhika Pawar
- Report ID: 2362
- Published Date: Jun 03, 2025
- Report Format: PDF, PPT
